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Abstract
We recently demonstrated that 12/15-lipoxygenase (LOX) derived metabolites, 
hydroxyeicosatetraenoic acids (HETEs), contribute to diabetic retinopathy (DR) via NADPH 
oxidase (NOX) and disruption of the balance in retinal levels of the vascular endothelial growth 
factor (VEGF) and Pigment Epithelium-Derived Factor (PEDF). Here, we test whether PEDF 
ameliorates retinal vascular injury induced by HETEs and the underlying mechanisms. 
Furthermore, we pursue the causal relationship between LOX-NOX system and regulation of 
PEDF expression during DR. For these purposes, we used an experimental eye model in which 
normal mice were injected intravitreally with 12/15HETE with/without PEDF. Thereafter, 
Fluorescein Angiography (FA) was used to evaluate the vascular leakage, followed by Optical 
coherence tomography (OCT) to assess the presence of angiogenesis. FA and OCT reported an 
increased vascular leakage and pre-retinal neovascularization, respectively, in response to 12-
HETE that were not observed in PEDF-treated group. Moreover, PEDF significantly attenuated 
the increased levels of vascular cell and intercellular adhesion molecules, VCAM-1 and ICAM-1, 
elicited by 12-HETE injection. Accordingly, the direct relationship between HETE and PEDF has 
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been explored through in-vitro studies using Müller cells (rMCs) and human retinal endothelial 
cells (HRECs). The results showed that HETEs triggered the secretion of TNF-α and IL-6, as well 
as activation of NFκB in rMCs and significantly increased permeability and reduced zonula 
occludens protein-1 (ZO-1) immunoreactivity in HRECs. All these effects were prevented in 
PEDF-treated cells. Furthermore, interest in PEDF regulation during DR has been expanded to 
include NOX system. Retinal PEDF was significantly restored in diabetic mice treated with NOX 
inhibitor, apocynin, or lacking NOX2 up to 80% of the control level. Collectively, our findings 
suggest that interfering with LOX-NOX signaling opens up a new direction for treating DR by 
restoring endogenous PEDF that carries out multilevel vascular protective functions.
Keywords
Diabetic Retinopathy; PEDF; 12/15-Lipoxygenase; 12/15 HETEs; Retinal vascular leakage; and 
retinal inflammation
INTRODUCTION
Diabetic retinopathy (DR) is a potentially sight-threatening disease characterized by retinal 
barrier breakdown leading to macular edema and induction of retinal neovascularization 
(RNV). Although the pathogenesis of DR is multi-factorial, including inflammation, 
oxidative injury, and endothelial structural as well as functional abnormalities, several 
studies have consistently reported that the disruption of the delicate balance between the 
levels of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor 
(PEDF) is a pathophysiological hallmark in the development of DR [1–3]. Consequently, 
restoration of this balance is a potential therapeutic target that would substantially 
ameliorate DR and the subsequent vision loss.
PEDF is a multifunctional, pleiotropic secretory glycoprotein first isolated from cultures of 
fetal retinal pigment epithelial cells [4] and is also expressed in different cell types of the 
eye [5]. PEDF has been reported to elicit antiangiogenic, antioxidative, and anti-
inflammatory properties [6, 7]; suggesting its use in the treatment of DR. Earlier clinical 
studies demonstrated an inverse relationship between endogenous PEDF level and the 
development of proliferative diabetic retinopathy (PDR) [8, 9]. Additionally, lower vitreous 
level of PEDF has been found to be associated with early phase of experimental DR [10], 
and that systemic or local delivery of recombinant PEDF protein or viral vector-mediated 
PEDF gene therapy successfully inhibited RNV and reduced retinal vascular permeability in 
an adult and chronic model of retinal neovascularization [11–13]. However, to maintain the 
sustained intraocular delivery of PEDF is a critical challenge. As such, restoration of 
endogenous PEDF offers an alternative dimension for DR therapy. To accomplish this 
objective the mechanisms by which diabetes suppresses PEDF must be dissected out.
Our recent study suggested that 12/15-lipoxygenase (LOX)-derived eicosanoids, 12-and 15-
hydroxyeicosatetraenoic acids or (HETEs), contribute to DR via disrupting the retinal 
balance between VEGF and PEDF [14, 15]. In addition, we have shown that NADPH 
oxidase (NOX), a major source of oxidative stress during DR [16], is a downstream 
mediator from HETEs [15]. The goals of the present study are to test if exogenous PEDF 
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protects retina against 12/15-HETEs-induced inflammation and microvascular injury such as 
hyperpermeability and neovascularization and to investigate whether NADPH oxidase has a 
regulatory effect on PEDF level in retina during diabetes.
MATERIALS AND METHODS
Animal Preparation and Experimental Design
All procedures with animals were performed in accordance with the Public Health Service 
Guide for the Care and Use of Laboratory Animals (Department of Health, Education, and 
Welfare publication, NIH 80–23) and Georgia Regents University guidelines. Eight-week-
old male NOX2, a catalytic subunit of NADPH oxidase, knockout (NOX2−/−) and 
corresponding littermate controls, wild-type (Wt) mice in C57BL/6J background (Jackson 
Laboratory, Bar Harbor, ME), were matched according to sex, age, and weight. All animals 
were maintained in clear plastic cages, subjected to standard 12-hour light/12-hour dark light 
cycles in the animal room at regulated temperature (22 to 24°C), and allowed to eat and 
drink ad libitum. Light levels at the bottom of cages were controlled at 1.5-foot candles 
(16.1 lux) to avoid the possibility of light damage in the retina.
Animals were given intraperitoneal (I.P) injections of freshly prepared streptozotocin (STZ, 
45 mg/kg, Enzo Life Sciences, Farmingdale, NY) dissolved in 0.9% NaCl after four hour-
fasting for 5 consecutive days. Diabetes was verified by blood glucose readings with mean 
of 412±30 mg/dL for diabetic mice versus 169±10 mg/dL for all non-diabetic controls. In 
pharmacologic studies, age-, weight- and sex-matched C57BL/6J mice were rendered 
diabetic and then treated with or without apocynin (Sigma, St. Louis, MO, 10 mg/kg) in 
drinking water for the duration of the study (n = 4–6/group). The dose of apocynin was 
chosen according to our previous studies [16, 17]. Five weeks after establishment of 
diabetes, retina samples were used for PEDF analysis by Western blot and frozen eye 
sections were prepared to examine PEDF distribution in retina by immunofluorescence. 
Average body weight was equal in all groups (Wt, 24.94 g ±1.6 SD Vs NOX2−/−, 25.2 g ± 
2.3 SD) prior to the induction of diabetes and increased slightly in the control non diabetic 
controls to be 27.8 g ±1.9 SD for Wt and 28.3 g ± 2.5 SD for NOX2−/−, compared with the 
three diabetic groups which did not change during the course of diabetes.
For intravitreal injections, the procedure was essentially the same as previously described 
[18]. Briefly, each mouse received an intramuscular injection of rodent anesthesia cocktail 
(ketamine 100 mg/kg, xylazine 10 mg/kg) in 0.1–0.2 ml of phosphate-buffered saline (PBS). 
Anesthetized mice were given eye drops of topical anesthesia (proparacaine HCl, Alcon, 
Fort Worth, Texas) as well as pupil dilator (tropicamide 1%, Alcon). 5-, 12-, or 15-HETE 
(Cayman Chemical, Ann Arbor, MI) was dissolved in ethanol and a working solution of 10× 
was prepared by diluting 0.32 μl of stock solution (312 μM) to 100 μl with PBS. Assuming 
the vitreous volume of mouse eye is ~ 5–7 μl [19], then by injecting 0.5 μl of this working 
solution in the presence of 0.5 μl containing 2 μg/μl PEDF purified as described previously 
[20] or PBS-vehicle, an 0.1 μM vitreal concentration of HETEs with or without 1 μg PEDF/
mouse eye was obtained. The vitreal concentration of ethanol was 0.032%. To ensure the 
proper delivery and even distribution of the intravitreally injected compounds, all solutions 
for intravitreal injection contained 5 μg/ml of Fast Green FCF (Sigma). The volume of the 
Ibrahim et al. Page 3
Biochim Biophys Acta. Author manuscript; available in PMC 2016 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
injected solution apparently did not cause significant pressure-induced retinal damage, 
because 0.032% ethanol-PBS-injected control eyes showed normal retinal morphology with 
no apparent apoptosis within 7 days. Intravitreal injections were performed using a 10-μL 
Hamilton syringe adapted with a 32-gauge microneedle. The needle tip was inserted into the 
superior hemisphere of the eye, at a 45° angle through the sclera into the vitreous body 
under the guidance of Stemi DV4 Stereo Microscope (Carl Zeiss, Inc., Thornwood, NY). 
This route of administration avoided retinal detachment or injury to eye structures, including 
the iris and lens, which release factors that induce neuronal survival [21]. Neomycin/
polymyxin B/bacitracin (Alcon) ophthalmic ointment was applied to the injected eyes. The 
mice recovered spontaneously from the anesthesia and then were sent back to the animal 
room with food and water ad libitum. The doses of 12/15-HETEs were chosen according to 
what detected previously in the vitreous of patients with DR, 50 ng/mL (~0.1–0.2 uM) [14], 
while the dose of PEDF was chosen according to what reported previously that PEDF 
efficiently inhibited ischemia-induced RNV and hyper-permeability at a dose of ~1–2 
μg/eye [20, 22].
Fluorescein Angiography (FA)
To evaluate retinal vasculature and permeability in vivo, one week after intravitreal 
injections, mice were anesthetized using intramuscular injection of rodent anesthesia 
cocktail described above. Pupils were dilated using 1% tropicamide eye drop. The mouse 
was placed on the imaging platform of the Phoenix Micron III retinal imaging microscope 
(Phoenix Research Laboratories, Pleasanton, CA), and Goniovisc 2.5% (hypromellose; 
Sigma Pharmaceuticals, LLC, Monticello, IA) was applied liberally to keep the eye moist 
during imaging. Mice were administered 10 to 20 μL 10% fluorescein sodium (Apollo 
Ophthalmics, Newport Beach, CA), and rapid acquisition of fluorescent images ensued for 
~5 minutes. Fluorescein leakage manifests as indistinct vascular borders progressing to 
diffusely hazy fluorescence. Fluorescein leakage was compared between different groups by 
quantifying the uorescence intensities collected after 1, 2, and 3 minutes following uorescein 
injection using ImageJ software (National Institutes of Health, Bethesda, MD).
Optical coherence tomography (OCT)
To assess the presence of angiogenesis, imaging of eyes was performed 3 weeks after 
intravitreal injections by using OCT imaging device coupled with Color Doppler imaging 
(Envisu OCT, Bioptigen, Inc., Morrisville, NC) with a 25-diopter lens fitted on a 30-degree 
angle lens. The pupils of anesthetized mice were dilated with 1% tropicamide eye drops 
before image acquisition. Lubricant Eye Gel (GenTeal; Novartis Pharmaceuticals, East 
Hanover, NJ) was used throughout the procedure to maintain corneal moisture and clarity. 
Three repeated-volume intensity projections were acquired for each eye. The images 
consisted of 100 averaged B-scans. Collection of the data permitted three-dimensional 
renderings of the retina. Doppler imaging was performed during the scan to visualize blood 
vessels.
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Immunofluorescence
Immunofluorescence analysis was performed using frozen retinal sections. Briefly, cryostat 
sections (10 μm) were fixed in 4% paraformaldehyde, blocked with 10% normal goat serum 
(NGS) and then incubated overnight at 4°C with primary antibody for PEDF (Millipore, 
Temecula, CA) or biotinylated isolectin B4 (Vector Laboratories, CA). Thereafter, sections 
were briefly washed with PBS and incubated with Texas red-labeled secondary antibody or 
Texas red-labeled streptavidin. Slides were examined by confocal microscopy (LSM 510, 
Carl Zeiss). Specificity of the reaction was confirmed by omitting the primary antibody. 
Images were collected from five sections per mouse of at least three mice in each group and 
then analyzed using Image J software to quantify the intensity of immunostaining.
Microvascular human retinal endothelial cells (HRECs)
HRECs (Cell Systems Corporation (CSC), Kirkland, WA, USA), passages 6–8, were grown 
on gelatin-coated dishes and maintained in M199 media supplemented with CSC endothelial 
growth factors, 1% penicillin/streptomycin, and 10% fetal bovine serum (FBS, Atlantic 
Biological, Norcross, GA, USA). After the cells formed a complete confluent layer, the cells 
were shifted to 1% FBS overnight, then treated with 0.1 μM of 15-HETE with or without 
PEDF (100 nM)-pretreatment. The experiment was terminated after 24 hours, then cells 
were fixed with 2% paraformaldehyde for 10 minutes and blocked with normal goat serum 
for one hour followed by incubation with zonula occludens (ZO)-1 antibody (Invitrogen, 
Eugene, OR, 1:100) overnight at 4°C before incubation with Oregon green labeled 
secondary antibody (1:500, Invitrogen, Eugene, OR). Images then were collected and color 
intensity was measured by Image J.
Assessment of HREC barrier function
HRECs were seeded on collagen/fibronectin coated membranes with 0.4 μm pores 
(Transwell; Corning Costar), in normal media. After becoming completely confluent cells 
were shifted to 1% serum media overnight then were treated by 0.1 μM 15-HETE in the 
presence or absence of PEDF (100 nM)-pretreatment in the apical chambers for 24 hours. 
Thereafter, fluorescein isothiocyanate (FITC)-dextran (1 mg/ml, 70 KD, Sigma) was added 
to the apical chambers followed by obtaining aliquots from the basolateral chamber every 30 
min for 4 h then measuring the fluorescence intensity with a plate reader. The rate of 
diffusive flux (Po) was calculated by the following formula [23]:
Where Po is in centimeters per second; FA is basolateral fluorescence; FL is apical 
fluorescence; Δt is change in time; A is the surface area of the filter (in square centimeters); 
and VA is the volume of the basolateral chamber (in cubic centimeters).
Rat Retinal Müller cells (rMC-1)
rMC-1 was obtained as a gift from Dr. V. Sarthy (Northwestern University, Chicago, IL). 
The cells were maintained in Dulbecco’s modified Eagle’s medium/Nutrient Mixture F-12 
(DMEM: F12, Mediatech Cellgro, Herndon, VA) supplemented with, 1% penicillin/
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streptomycin, and 10% FBS. To determine the effect of 12-HETE on Interleukin (IL)-6 and 
Tumor Necrosis Factor (TNF)-α expression in rMC-1, 12-HETE was added to the cultured 
rMC-1 (0.1 μM in serum-free DMEM:F12) with/without PEDF. By the end of the 
experiment (after 72 h), rMC-conditioned media were collected and processed for enzyme-
linked immunosorbent assay (ELISA) to detect IL-6 as well as TNF-α, while cell 
homogenates were analyzed by Western blotting for NF-κB.
Enzyme-linked immunosorbent assay (ELISA) for IL-6 and TNF-α
IL-6 and TNF-α levels in the supernatants of culture media were estimated with ELISA kits 
(R & D, Minneapolis, MN) per the manufacturer’s instructions. Standards and samples were 
added and bound by the immobilized antibody. After washing, an enzyme-linked polyclonal 
antibody specific for the cytokine was added to the wells followed by a substrate solution 
yielding a colored product. The intensity of the color was measured at 450 nm and corrected 
at 540 nm.
Protein extraction and Western blot analysis
Washed cultured cells as well as retinal tissues were lysed in modified RIPA buffer 
(Upstate, Lake Placid, NY), supplemented with 40 mM NaF, 2mM Na3VO4, 0.5 mM 
phenylmethylsulfonyl fluoride, and 1:100 (v/v) of proteinase inhibitor cocktail (Sigma). 
Insoluble material was removed by centrifugation at 12,000 xg at 4°C for 30 min. Protein 
was determined by DC Protein Assay (Bio-Rad, Hercules, CA) and 50 μg was boiled in 
Laemmli sample buffer, separated by SDS-PAGE on a gradient gel (4 to 20%, Pierce, 
Rockford, IL), transferred to nitrocellulose membrane and incubated with specific 
antibodies. Antibodies for PEDF, β-actin (Sigma), ICAM-1, (Santa Cruz Biotechnologies, 
Santa Cruz, CA), VCAM-1, pNFκB, and NFκB (Cell Signaling Technology, Beverly, MA), 
were detected with a horseradish peroxidase-conjugated antibody and enhanced 
chemiluminescence (Amersham, Pittsburgh, PA). Intensity of immunoreactivity was 
measured by densitometry using Image J software.
Data Analysis
The results are expressed as mean ± SD. Statistical analysis was performed using one-way 
analysis of variance (ANOVA) with Tukey Kramer post-hoc test for multiple group 
comparisons. A confidence level of P<0.05 was considered statistically significant.
RESULTS
Effect of PEDF on retinal vascular abnormalities induced by 12/15-
hydroxyeicosatetraenoic acids (HETEs)
12/15-LOX-derived metabolites have been shown to contribute significantly to DR via 
disrupting the balance between VEGF and PEDF [14]. In the same study we have reported 
that treatment of rMC1 with 12-HETE reduced the expression of PEDF and increased VEGF 
production. Therefore, we questioned whether restoring PEDF using exogenous-PEDF 
peptide would ameliorate retinal vascular injury induced by these eicosanoids. Toward this 
goal, initially we used an experimental eye model in which normal mice were injected 
intravitreally with the most common metabolite analogs derived from LOX (5-, 12-, 15-
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HETE) or solvent control. One week later, FA was used to evaluate retinal vascular leakage. 
As shown in Figure 1, 12-HETE-injected eyes had the most increased fluorescein leakage 
among the three types of HETE- injected mice compared with the solvent-injected controls. 
Secondly, the co-administration of PEDF with 12-HETE significantly reduced the 12-
HETE-induced retinal vascular leakage, Figure 1.
This finding of PEDF’s protective effect against increased retinal permeability in mice 
receiving 12-HETE has been substantiated in human retinal endothelial monolayer treated 
with 15-HETE. Of note, species-specific difference between orthologous LOX isoforms has 
been described for the murine 12-LOX, which is an arachidonate 15-LOX in human. This 
difference indicates that care should be taken if experimental data on LOX metabolism are 
being transferred from one species to another [24, 25]. Accordingly, we have used 12-HETE 
in all murine experiments versus 15-HETE in all human cell experiments. With HREC 
model, we examined whether 15-HETE induces permeability changes to FITC dextran flux 
through the confluent monolayer. We noticed that 15-HETE-treated HRECs became 
significantly permeable to FITC-dextran as indicated by increasing diffusive flux (Po) for 
FITC-dextran. However, PEDF significantly reduced the effect of 15-HETE on FITC-
dextran leakage (Figure 2A). Additionally, we investigated if 15-HETE modulates the 
expression of ZO-1, a tight junction protein that is crucial in maintaining the barrier 
function. As shown in Figure 2B and quantified in 2C, a smooth and continuous staining for 
ZO-1 along the intercellular borders of endothelial cells was seen in vehicle-treated controls. 
However, the exposure of HRECs to 15-HETE caused a noticeable alteration of ZO-1 
spreading at cellular border, displaying less immunoreactivity. These effects induced by 15-
HETEs were significantly reversed by pre-treatment with PEDF.
Following this further, we used OCT to evaluate the angiogenic activity of 12-HETE in the 
presence or absence of PEDF. Normally there are no blood vessels located in the vitreous 
cavity or pre-retinal space. As shown in Figure 3A, OCT imaging of mouse retina after 3 
weeks from the 12-HETE injection showed pre-retinal neovascularization as confirmed by 
Color Doppler Imaging, hematoxylin and eosin (H&E) staining (Figure 3B), three 
dimensional OCT imaging (Figure 3C), and immunofluorescence with isolectin B4 as a 
marker of capillary endothelial cells (Figure 3D). On the other hand, these new vessels were 
not observed in PEDF-treated group, implying its anti-angiogenic activity.
Effect of PEDF on retinal inflammatory response induced by 12-HETE
An increase in retinal vascular permeability is a hallmark of inflammation. Given this fact, 
we next sought to determine whether the beneficial effect of PEDF on 12-HETE-induced 
retinal vascular leakage would associate with a reduction in the inflammatory response. In 
this regard, we have determined the effect of PEDF on 12-HETE-induced increases in levels 
of VCAM-1 and ICAM-1, well established markers of endothelial dysfunction in 
inflammatory conditions [26]. Western blot analysis showed significant increases in the 
expression of VCAM-1 and ICAM-1 in 12-HETE-injected eyes compared with vehicle-
injected controls. Co-administration of PEDF significantly attenuated the increases in 
VCAM-1 and ICAM-1 levels elicited by 12-HETE injection (Figure 4 A and B).
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Next we aimed to explore a potential mechanism by which PEDF signaling regulates the 
retinal inflammation induced by 12-HETE. To do this, additional studies using retinal 
Müller cells (rMCs) treated with 12-HETE were performed. rMCs were chosen here because 
they have been recognized as a potential source contributing to the retinal inflammatory 
outcome during diabetes [27]. rMCs have been shown to be activated by hyperglycemia to 
produce inflammatory cytokines in NFκB-dependent mechanism [28]. With the use of this 
model, we first verified whether 12-HETE could stimulate inflammatory cytokine 
production such as IL-6 and TNF-α from rMCs. IL-6 and TNF-α, were selected as 
biomarkers of inflammation because they have been shown to be more consistently elevated 
in DR contributing to blood-retinal barrier (BBB) permeability changes and their 
proinflammatory immune functions [29–32]. As shown in Figure 5 A and B, there were 
prominent increases in IL-6 as well as TNF-α production in the conditioned media of rMCs 
incubated with of 12-HETE (0.1 μM) compared with the vehicle-treated cells. Secondly, we 
characterized the effect of PEDF on pro-inflammatory cytokine levels produced by 12-
HETE in rMCs. As shown in Figure 5, PEDF potently inhibited the 12-HETE-induced IL-6 
and TNF-α expression in rMCs. Lastly, we pursued the molecular mechanisms by which 
PEDF mediating its anti-inflammatory effects in 12-HETE-treated rMCs. Since we have 
shown previously that 12-HETE generates ROS [15] which modulate a number of gene 
expression through the activation of transcriptional factor NF-κB [33], we tested the effect 
of 12-HETE on NF-κB activation and the modulation effects of PEDF. As shown in Figure 
5C, 12-HETE had significantly increased the level of pNF-κB compared to the control 
group. PEDF on the other hand, was found to partially, but significantly, block the effect of 
12-HETE on NF-κB activation. Collectively, these results suggest that the retinal protective 
effect of PEDF is mediated by abrogating the inflammatory response induced by 12-HETE 
via suppression of NF-κB pathway.
Role of NADPH oxidase in diabetes-induced retinal PEDF suppression
After having shown the salutary effects of PEDF on the impairment of retinal vascular 
functions induced by 12-HETE injection, interest in its regulation during DR has been 
expanded to include LOX-NADPH oxidase pathway. 12/15-LOX has been suggested as a 
potential contributor to vascular hyperpermeability during DR via NADPH oxidase 
dependent mechanism [15]. Whether or not LOX-NADPH oxidase pathway modulates 
PEDF expression during diabetes was also examined here. To test our hypothesis, we treated 
diabetic and non-diabetic mice with/without NADPH oxidase inhibitor, apocynin, and 
determined its effect on diabetes-induced retinal PEDF suppression. Western blot analysis 
followed by densitometric analysis showed that level of PEDF was decreased by 50% in the 
retina of 5-weeks diabetic mice compared with non-diabetic retinas (Figure 6A). Treatment 
of the diabetic animals with apocynin significantly restored the normal level of PEDF in the 
diabetic mice up to 80% of the control level. Moreover, PEDF-like epitopes were featured 
within the retinal tissue of normal mice to be localized in inner retina as well as in retinal 
pigment epithelium (RPE) layer. However, PEDF immunoreactivity observed in inner retina 
was significantly decreased by diabetes and the treatment with apocynin resulted in a 
marked recovery of its immunoreactivity within diabetic retina (Figure 6B).
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To further assess the role of NADPH oxidase in mediating PEDF suppression during 
diabetes, we studied the effects of NOX2 ablation on diabetes-induced retinal PEDF 
suppression. Comparative analysis of PEDF level in retina samples revealed that PEDF in 
the diabetic NOX2−/− mice was increased significantly compared with the diabetic Wt 
littermates and brought back closer to normal level (Figure 6A). Moreover, PEDF 
immunofluorescence reactivity in the retinas of diabetic NOX2−/− mice was greatly 
improved and back to 80% of normal level compared with their age-matched diabetic Wt 
littermates (Figure 6B). Taken together, these results clearly demonstrate that NOX pathway 
plays a crucial role in mediating retinal PEDF-suppression associated with diabetes.
DISCUSSION
Although the protective effect of PEDF in DR is generally considered to be a potential 
therapeutic strategy, its regulation and mechanism of action are not yet well identified. In 
this study, we put forward a new concept pertaining to the protective role of PEDF against 
12/15-LOX derived hydroxyeicosanoids-induced retinal endothelial dysfunctions. 
Furthermore, our study provides a preclinical evidence for the involvement of NADPH 
oxidase pathway in the regulation of PEDF level during DR.
In recent years, a growing body of evidence has highlighted the role of 12/15-LOX pathway 
as a contributing factor to various retinal vascular diseases including DR. Our recent studies 
reported that retinal expression and activity of 12/15- LOX are associated with increased 
vascular leakage and NV, the hallmark features of DR. Moreover, inhibition of 12/15-LOX 
demonstrated beneficial effects in attenuating the early inflammatory response and RNV in 
experimental models of DR and oxygen-induced retinopathy, respectively [14, 15]. 
Furthermore, the in vitro studies on retinal vascular endothelial cells incubated with 12/15 
HETEs have shown increases in ROS generation, NOX2 expression, and VEGF-R2 
phosphorylation together with decreased pSHP1 expression [15]. As such, targeting 12/15-
LOX signaling system by an agent carries out multilevel protective functions may open up a 
new direction for treating DR.
PEDF is a versatile multifunctional endogenous protein involved in a variety of biochemical 
functions. PEDF has been documented by numerous studies to inhibit endothelial cell 
proliferation and migration which can prevent the growth of new blood vessels in retina 
during pathological conditions [34–36]. PEDF also reduced VEGF-induced hyper-
permeability in retinal microvascular endothelial cells [22, 37]. Beyond PEDF’s 
antiangiogenic activity, PEDF has been well recognized for its neuroprotective, anti-
inflammatory, and antioxidant properties [22, 38–40]. Given these functions, PEDF 
represents a potential intervention therapy for DR. These beneficial effects of PEDF were 
correlated with the decreased levels of retinal inflammatory factors, including VEGF, VEGF 
receptor-2, MCP-1, TNF-α, and ICAM-1 [22]. In concordance with these previous studies, 
we reported similar findings for the beneficial effects of PEDF in decreasing abnormalities 
in retinal microcirculation functions. However, this study is the first to extend the 
knowledge of PEDF’s anti-permeability, anti-angiogenic, and anti-inflammatory effects to 
include its ability to counteract retinal endothelial dysfunctions in response to 12/15-HETEs.
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Accordingly, the direct relationship between HETEs and PEDF has been explored through 
in vitro studies using two critical cell types of the eye, rMCs and HRECs. The results of 
these experiments demonstrated that 12/15-HETEs trigger the secretion of TNF-α as well as 
IL-6 from rMCs and this inflammatory response is associated with activation of NFκB in 
rMCs and alteration of ZO-1 protein dynamics in HRECs. NF-κB is a pleiotropic regulator 
of many pro-inflammatory cytokines that has been found to be activated by a variety of 
stimuli, including diabetic stress [41, 42]. All these effects were prevented in PEDF-treated 
cells.
Despite the aforementioned rescue effects of PEDF, its application is limited by its short 
half-life, unstable pharmacology, and administration pathway. The gene therapy method, 
such as adeno-associated virus vector-(AAV) mediated PEDF, has been used to overcome 
the limitations accompanied the topical application of recombinant PEDF [44–46]. 
However, because of possible immunogenicity properties associated with AAV, PEDF 
application is still limited [47]. These limitations prompted us to find an efficient way to 
maintain PEDF expression and action in the diabetic retina. This approach requires 
deciphering the molecular events underlying the disruption of PEDF expression during 
diabetes.
Previous studies showed that PEDF suppressed the VEGF-, advanced glycation end 
products-, and diabetes-induced leukostasis and vascular permeability[6, 37, 48] via 
inhibition of NADPH oxidase-mediated ROS generation and NFκB signaling pathway [49–
51]. However, the reverse relationship between NADPH oxidase and PEDF is not yet clear 
and needs extensive investigation. Previously, we have shown that 12-HETE attenuated the 
levels of PEDF. Furthermore, we have shown that NADPH oxidase is a major downstream 
mediator from HETEs. These findings, together with our observations that NOX2 deletion 
resulted in a marked recovery of PEDF’s immunoreactivity within diabetic retina, have 
underpinned the notion that LOX-NOX pathway plays a crucial role in retinal PEDF-
suppression during diabetes.
In summary, taken together our previous and current studies provide new insights into the 
mechanisms of how diabetes affects the expression of PEDF in the retina, demonstrating 
that signaling through LOX-NOX pathway is a critical pathway for down-regulating PEDF. 
Additionally, our results suggest that interfering with the LOX-NOX pathway may represent 
a novel mechanism by which PEDF exerts its broad effects against DR and other retinal 
microvascular dysfunctions associated with increased eicosanoids. Figure 7 illustrates the 
hypothetical mechanisms in the causal inference between these biomolecular pathways in 
DR.
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List of Nonstandard Abbreviations
DR diabetic retinopathy
12/15-LOX 12/15-Lipoxygenase
NOX NADPH oxidase
HETEs 12- and 15-hydroxyeicosatetraenoic acids
PEDF pigment epithelium-derived factor
TNF-α tumor necrosis factor-α
VEGF vascular endothelial growth factor
ELISA Enzyme-linked immunosorbent assay
ROS reactive oxygen species
STZ Streptozotocin
HRECs human retinal endothelial cells
rMCs retinal Müller cells
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Highlights
• 12/15-HETEs induce a phenotype of DR, increased permeability and 
neovascularization.
• PEDF inhibits 12/15HETEs-induced retinal microvascular dysfunctions.
• NADPH oxidase regulates retinal PEDF level during diabetes.
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Figure 1. Anti-permeability effect of PEDF on HETEs-induced retinal vascular leakage assessed 
by fluorescein angiography
A) Fluorescein angiography (FA) of normal C57BL/6J mice injected intravitreally with 
vehicle (control), 5-HETE, 15-HETE, or 12-HETE with/without PEDF. FA pictures were 
obtained one week post-injection to evaluate the changes of retinal vascular leakage. Data 
are representative of 4–6 mice studied in each group. B) Quantification of fluorescein 
intensity per mouse retina among studied groups relative to control (vehicle injected).
Ibrahim et al. Page 16
Biochim Biophys Acta. Author manuscript; available in PMC 2016 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Effect of PEDF on 15-HETE-induced increase in permeability and alteration in ZO-1 
expression in human retinal endothelial cells (HRECs)
A) Fold change in diffusive flux (Po) of 70-kDa-dextran evaluated after 24 hours of 15-
HETE treatment in absence or presence of PEDF (100 nM), relative to control group 
(vehicle). B) Immunofluorescence of ZO-1 (green) in HRECs treated by 15-HETE in 
presence or absence of PEDF. C) Quantification of ZO-1 immunofluorescence staining in 10 
fields/slide normalized as percentage of control group (vehicle). Data shown are the mean ± 
SD of 3 independent experiments. Results show a significant decrease in ZO-1 expression 
by 15-HETE-treatment that was restored by PEDF-pretreatment. The Blue staining (DAPI) 
is a nuclear marker.
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Figure 3. Anti-angiogenic effect of PEDF on 12-HETE-induced retinal neovascularization
Normal C57BL/6J mice were injected intravitreally with vehicle or 12-HETE with/without 
PEDF. A) Optical coherence tomography (OCT) B-scan reported a pre-retinal 
neovascularization (arrow) in mouse eye receiving 12-HETE as confirmed by Color Doppler 
imaging that enabled vascular imaging in false-colors (red–blue). The red or blue color 
corresponds to blood flow in the direction towards or away from the incident OCT beam. 
Meanwhile, these new vessels were not observed in the examined PEDF-administered mice. 
B) Enlarged OCT picture for the boxed areas in Figure 3A supplemented with hematoxylin 
and eosin (H&E) staining for the areas that show pre-retinal neovascularization in mouse 
eye receiving 12-HETE. C) Three dimensional OCT (3D-OCT) imaging of the retina. The 
vehicle-injected eye shows clear tomographic in the vitreous while 12-HETE-injected eye 
has aberrant structures in vitreous corresponding to the presumptive vitreal blood vessels 
observed in the B-scan (arrow). These new vessels were not observed in PEDF-administered 
group. D) Retinal sections stained with isolectin-B4 (endothelial cell marker) to label retinal 
vasculature from mice injected intravitreally with vehicle, or 12-HETE with/without PEDF. 
Arrows point to pre-retinal neovascularization in 12-HETE-injected mice. Nuclei were 
counter-stained with DAPI (blue). Scale bar = 10 μM, data are representative of 4–6 mice 
studied in each group. ). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer 
nuclear layer.
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Figure 4. Anti-inflammatory effect of PEDF on 12-HETE-induced retinal inflammation 
evaluated by Western blot analysis for VCAM-1 and ICAM-1
Normal C57BL/6J mice were injected intravitreally with vehicle control or 12-HETE with/
without PEDF. The animals were sacrificed one week later, and retinas were dissected and 
prepared for Western blot analysis. A and B) Western blot and densitometric analysis of 
retinal expression of VCAM-1 and ICAM-1, respectively. VCAM-1 or ICAM-1 intensity 
relative to the actin for groups injected with 12-HETE with/without PEDF were quantified 
as percentage of vehicle injected group. Data shown are representative of 4–6 mice studied 
in each group.
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Figure 5. Identification of PEDF anti-inflammation signaling in retinal Müller cells
Levels of inflammatory cytokines, (A) Tumor necrosis factor (TNF)-α, and (B) Interleukin 
(IL)-6, were determined in the conditioned media of retinal Müller cells treated with 12-
HETE (0.1μM, 24 hours), in the presence or absence of pigment epithelium-derived factor 
(PEDF, 100 nM). TNF-α as well as IL-6 levels were determined by enzyme-linked 
immunosorbent assay (ELISA). Data shown are the mean ± SD of three experiments. C) 
Western blot analysis of Phospho-NF-κB p65 in extracts from Müller cells treated 24 hours 
with vehicle (control), 12-HETE (0.1μM) in presence or absence of pigment epithelium-
derived factor (PEDF, 100 nM), using Phospho-NF-κB p65 (Ser536) antibody (top) or NF-
κB p65 antibody (bottom). Ratios of the Phospho-NF-κB p65 intensity relative to the NF-
κB p65 for groups treated with 12-HETE with/without PEDF were compared 
densitometrically as percent of vehicle-treated group (control). Data shown are the mean ± 
SD of three experiments.
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Figure 6. NADPH oxidase inhibition or NOX2 ablation restored diabetes-induced retinal 
pigment epithelium-derived factor (PEDF) suppression
Using streptozotocin, diabetes was induced in 8 weeks old NOX2−/− mice and age-matched 
wild-type (Wt) littermates. One group of Wt diabetic mice was treated with a NADPH 
oxidase inhibitor, Apocynin (Apo) (10 mg/kg) in drinking water for the duration of the 
study, 5-weeks. A) Western blot analysis of PEDF in retinal samples from Wt (normal), 
diabetic Wt, diabetic NOX2 −/−, and apocynin-treated diabetic WT mice (Diabetic Wt + 
Apo). PEDF intensity relative to the actin for all diabetic groups are presented as percentage 
of Wt. (n = 4 to 6). B) Representative photomicrographs of PEDF distribution in the retinal 
sections from Wt, diabetic Wt, diabetic NOX2−/−, and Diabetic Wt + Apo. Quantification of 
retinal PEDF immunofluorescence in these micrographs as a percent of Wt (normal) was 
carried in 10 adjacent locations along the vertical meridian within 4 mm of the optic disk (10 
fields/retina section) (n = 4 to 6). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, 
outer nuclear layer.
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Figure 7. Proposed signaling pathways for the novel mechanism in treating diabetic retinopathy
Diabetes-induced 12/15-LOX activation leads to 12/15-HETEs formation that activates 
NADPH oxidase resulted in PEDF suppression, increased inflammation, and eventually 
vascular abnormalities (hallmarks of diabetic retinopathy).
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